Curated news and analysis on clinical trials, drug approvals, and medical research.
Polaryx Therapeutics has selected a contract research organization to conduct SOTERIA, a phase 2 trial evaluating PLX-200 across four rare lysosomal storage disorders, with trial initiation planned for the first half of 2026.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
Johnson & Johnson announced a $1 billion cell therapy manufacturing facility in Pennsylvania while reportedly exploring a sale of its DePuy Synthes orthopedics business for over $20 billion.
A Boston University study of 614 brains found that advanced chronic traumatic encephalopathy (CTE) from repeated head impacts significantly increases dementia risk, with stage IV CTE making individuals 4.5 times more likely to have dementia.
The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization for Moderna's mCOMBRIAX, the world's first combination Covid-19 and influenza vaccine, for individuals 50 years and older.
Secondary analysis of KEYNOTE-716 trial finds adjuvant pembrolizumab improves recurrence-free survival in stage IIB/IIC melanoma without increasing new primary melanoma risk, while reducing non-melanoma skin cancers.
A quantum computer integrated with Japan's Fugaku supercomputer has executed the first full scientific workflow for simulating chemical reactions in biomolecules, marking a transition from infrastructure development to practical deployment in drug discovery applications.
Healthcare systems worldwide are addressing polypharmacy as a major public health issue, with new guidance emphasizing person-centered medication reviews and risk mitigation strategies across multiple clinical settings including infectious disease care.
Relay Therapeutics reported full-year 2025 revenue of $15.36 million and a narrowed net loss of $276.48 million, while securing FDA Breakthrough Therapy designation for lead asset zovegalisib. The company filed a $96.18 million shelf registration.
Health Secretary Robert F. Kennedy Jr. is drawing criticism from anti-vaccine supporters who believe he has not gone far enough in dismantling vaccine programs, following regulatory reversals including the restoration of an mRNA flu shot review.
Researchers are developing gene therapy approaches for neurological disorders and head and neck conditions, using viral vectors and advanced delivery methods to treat brain tumors, Alzheimer's, and Parkinson's disease.
Ocugen has completed enrollment of 140 patients in its Phase 3 liMeliGhT trial for OCU400, a gene therapy for retinitis pigmentosa. Topline data expected in Q1 2027 could support potential approval later that year.
Phase III trial of 196 patients shows stereotactic radiation targeting individual tumors significantly improved symptom burden and daily functioning compared with hippocampal-avoidance whole-brain radiation, without compromising survival.
Multiple organizations submitted comments opposing CMS's proposed GLOBE and GUARD models, which would tie Medicare drug reimbursement to international reference prices. Critics argue the models function as price controls that could undermine pharmaceutical innovation.
Canada's Drug Agency issued a draft recommendation against public drug plan coverage for lecanemab, an Alzheimer's treatment conditionally approved by Health Canada in October 2025, citing cost concerns despite the drug's ability to slow cognitive decline.
AbbVie announced positive topline results from the Phase 3 AFFIRM study showing risankizumab subcutaneous induction achieved superior clinical remission and endoscopic response rates versus placebo in adults with moderately to severely active Crohn's disease.
The pharmaceutical industry is experiencing recovery driven by innovation in drug development, aggressive M&A activity, and expansion of drug development services. The sector faces both opportunities and headwinds including pipeline setbacks and regulatory pressures.
Two major partnerships in India's diagnostics sector aim to strengthen precision medicine capabilities. MedGenome acquires majority stake in Medcare Management Services, while SRMIST partners with CORE Diagnostics to train future oncology professionals.
Recent studies examine biological factors affecting sleep in older adults, finding connections between inflammatory markers, antioxidant capacity, and sleep quality in aging populations.
The FDA has accepted New Drug Applications for rusfertide in polycythemia vera with Priority Review and tirabrutinib for relapsed/refractory primary CNS lymphoma under Accelerated Approval, with PDUFA dates set for Q3 2026 and December 2026 respectively.
